Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOL-116 in healthy subjects and rheumatoid arthritis patients
NCT05576012Phase 1Completed
- Sponsor
- Lipum AB
- Start
- Oct 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing SOL-116 with Placebo (2 arms). Primary endpoints: Adverse Events at 169 days, Injection Site Reactions at 169 days and 6 more. Started Oct 2022; status: completed.
02
Drugs
SOL-116
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05576012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05576012.